Oral Semaglutide (Wegovy Pill) - FDA Approved December 2025: According to the OASIS 4 trial published in the New England Journal of Medicine, participants who took the Wegovy pill experienced 13.6% mean weight loss over approximately 64 weeks when including all participants regardless of adherence, compared to 2.2% for those taking placebo
Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentration)
Ali Landry's new book, Reshape Your Life: Don't Settle Because You Are Worth It is available now in bookstores and Amazon
Core Mechanisms Recap: NNMT Inhibition: Prevents NAD depletion, supporting energy production and metabolic flexibility
Signs of dehydration include dark urine, dizziness, dry mouth, and reduced urination frequency